Data / Research funding / Texas / Texas Biomedical Research Institute
Texas Biomedical Research Institute: 56 NIH awards ($140.4M), fiscal years 2021 to 2026
Texas Biomedical Research Institute in San Antonio, TX is funded under 56 NIH awards ($140.4M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- J4EYPCJDQ1H6
- State
- Texas
Awards
56 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| The Southwest National Primate Research Center | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $46,064,371 | June 6, 1999 | April 30, 2026 | SCHLESINGER, LARRY S. | reporter.nih.gov |
| Establishment of a SPF Rhesus Macaque Colony | NIH | Office of the Director, National Institutes of Health | 2021 to 2025 | $12,897,251 | September 30, 2000 | January 31, 2027 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Further expansion of the Southwest National Primate Research Center Specific Pathogen Free Rhesus Macaque Resource | NIH | Office of the Director, National Institutes of Health | 2023 | $8,000,000 | September 8, 2023 | April 30, 2027 | MALLORY, AMBER | reporter.nih.gov |
| Durable HIV Vaccine Targeting Mucosal Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,751,308 | August 1, 2022 | July 31, 2027 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Interdisciplinary NexGen TB research Advancement Center (IN-TRAC) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,649,066 | March 10, 2022 | February 28, 2027 | SCHLESINGER, LARRY S. | reporter.nih.gov |
| Understanding Co-morbidities: COVID-19 in individuals living with HIV/AIDS | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,900,756 | February 1, 2022 | January 31, 2027 | SINGH, DHIRAJ KUMAR | reporter.nih.gov |
| Brain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradication | NIH | National Institute of Mental Health | 2022 to 2025 | $3,268,167 | April 5, 2022 | February 28, 2027 | LING, BINHUA "JULIE" | reporter.nih.gov |
| Epigenetic mechanisms underlying cannabinoid modulation of neuroinflammation in HIV/SIV infection | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,267,557 | September 30, 2020 | June 30, 2026 | MOHAN, MAHESH | reporter.nih.gov |
| Genomic consequences of schistosome hybridization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,122,895 | September 27, 2021 | August 31, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,782,422 | September 1, 2000 | November 30, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,692,722 | April 6, 2023 | August 8, 2025 | TORRELLES, JORDI B | reporter.nih.gov |
| Microbiome-mediated therapies for aging and healthspan in marmosets | NIH | National Institute on Aging | 2021 to 2024 | $2,592,378 | September 30, 2020 | May 31, 2025 | ROSS, CORINNA NICOLE | reporter.nih.gov |
| Host-Directed Therapy to Augment anti-M. tuberculosis Responses in the Setting of HIV Co-infection and to Sterilize the Tuberculoma | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,391,699 | May 16, 2018 | April 30, 2025 | MEHRA, SMRITI | reporter.nih.gov |
| Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,354,572 | August 7, 2019 | July 31, 2030 | SCHLESINGER, LARRY S. | reporter.nih.gov |
| Mechanisms of efficient control of Mycobacterium tuberculosis in the lungs prior to granuloma | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,322,288 | July 9, 2024 | May 31, 2029 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Significant expansion of the SNPRC Specific Pathogen Free Rhesus Macaque Colony for AIDS research | NIH | Office of the Director, National Institutes of Health | 2021 | $1,996,771 | September 1, 2021 | May 31, 2026 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Role of cellular long non-coding RNAs in HIV replication and disease outcome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,970,200 | August 1, 2022 | July 31, 2027 | KULKARNI, SMITA | reporter.nih.gov |
| Intrarectal Immunization for a Barrier to Mucosal HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,888,173 | April 19, 2024 | February 28, 2029 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Use of Focused ultrasound stimulated blood brain barrier opening for CNS HIV/SIV reservoir reduction | NIH | National Institute on Drug Abuse | 2025 | $1,825,990 | September 1, 2025 | May 31, 2030 | MOHAN, MAHESH | reporter.nih.gov |
| Modulating Indoleamines to Optimize Immunity in the Setting of Mtb/HIV Co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,820,801 | June 21, 2024 | April 30, 2029 | MEHRA, SMRITI | reporter.nih.gov |
| SigH based attenuated, efficacious Mtb vaccines to protect against lethal TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,745,052 | May 17, 2018 | April 30, 2025 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Viral and host determinants of donor-specific anti-HIV/SIV immunity mediated by APOBEC3-enzyme | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,679,173 | June 21, 2024 | April 30, 2029 | EBRAHIMI, DIAKO | reporter.nih.gov |
| Advancing Innovative Next_generation Heterologous Vaccines Against Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,615,572 | May 10, 2022 | April 30, 2026 | BEAMER, GILLIAN L | reporter.nih.gov |
| CNS Myeloid Cells as SIV Reservoirs: Persistent Infection and Rebound | NIH | National Institute of Mental Health | 2021 to 2022 | $1,407,298 | April 1, 2018 | January 31, 2024 | LING, BINHUA "JULIE" | reporter.nih.gov |
| Impact of HIV on the human alveolar environment drivingthe early events of Mycobacterium tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,384,896 | August 16, 2024 | August 8, 2025 | TORRELLES, JORDI B | reporter.nih.gov |
| Mathematical modeling of Mycobacterium tuberculosis dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,312,263 | April 22, 2022 | March 31, 2027 | GANUSOV, VITALY V. | reporter.nih.gov |
| M. tuberculosis metabolites to activate human mucosal-associated invariant T cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,256,392 | June 1, 2023 | May 31, 2028 | HUANG, SHOUXIONG | reporter.nih.gov |
| Targeted CRISPR/Cas Editing to Eliminate SIV CNS Reservoir in Methamphetamine-Exposed Rhesus Macaques on ART | NIH | National Institute on Drug Abuse | 2025 | $1,144,344 | August 15, 2025 | May 31, 2030 | LING, BINHUA "JULIE" | reporter.nih.gov |
| It's Contagious! Promoting the Biomedical Workforce Pipeline through Infectious Diseases | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,039,931 | July 1, 2022 | May 31, 2027 | RIGGS, ROSEMARY | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $923,047 | September 1, 2000 | November 30, 2022 | ANDERSON, TIM J | reporter.nih.gov |
| Evaluating the safety, immunogenicity and efficacy of a robust attenuated Mtb vaccine in the setting of HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $905,998 | June 17, 2025 | May 31, 2030 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Characterization of Marmosets as a Geroscience Model by the San Antonio MAP | NIH | National Institute on Aging | 2021 to 2022 | $904,240 | September 15, 2020 | May 31, 2025 | ROSS, CORINNA NICOLE | reporter.nih.gov |
| Immune Correlates of Protection from TB | NIH | National Institute of Allergy and Infectious Diseases | 2022 | $889,259 | July 1, 2017 | June 30, 2024 | KAUSHAL, DEEPAK | reporter.nih.gov |
| Donor-specific anti-HIV/SIV immunity mediated by APOBEC3 enzymes | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $833,457 | April 1, 2023 | March 31, 2025 | EBRAHIMI, DIAKO | reporter.nih.gov |
| Predicting tuberculosis outcomes using genotypic and biomarker signatures | NIH | National Heart, Lung, and Blood Institute | 2023 | $802,668 | January 15, 2019 | December 31, 2025 | BEAMER, GILLIAN L | reporter.nih.gov |
| Single cell trancriptomics to identify LTBI reactivation markers in TB/HIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $799,839 | August 18, 2022 | July 31, 2025 | SHARAN, RITI | reporter.nih.gov |
| Pigtail Macaque Model of Human-Simian Immunodeficiency Virus Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $756,000 | August 12, 2022 | July 31, 2025 | THIPPESHAPPA, RAJESH | reporter.nih.gov |
| Effect of IL-21 treatment concurrent to ART and 3HP in Mtb/SIV co-infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $718,758 | September 1, 2024 | August 31, 2025 | SHARAN, RITI | reporter.nih.gov |
| Characterizing IL-22 driven chronic immune activation in HIV/TB co-pandemic | NIH | Office of the Director, National Institutes of Health | 2021 to 2023 | $566,664 | April 1, 2021 | January 31, 2025 | SHARAN, RITI | reporter.nih.gov |
| The role of macrophage podosomes in Ebola virus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $544,500 | November 12, 2020 | October 31, 2023 | SHTANKO, OLENA | reporter.nih.gov |
| Nanobody toolkit for human coronavirus classification | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $544,500 | March 19, 2021 | February 29, 2024 | HAYHURST, ANDREW | reporter.nih.gov |
| Tunneling nanotubes as an alternate route of Ebola virus dissemination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $544,500 | February 1, 2021 | January 31, 2024 | SHTANKO, OLENA | reporter.nih.gov |
| Role of the microbiome of the schistosome snail host | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $544,500 | May 26, 2022 | April 30, 2025 | CHEVALIER, FREDERIC DAVID | reporter.nih.gov |
| Novel antiviral strategy offering forward capability and reduced risk of escape | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $544,500 | April 4, 2023 | March 31, 2026 | HAYHURST, ANDREW | reporter.nih.gov |
| Modeling chikungunya virus neuroinvasion and neuropathogenesis in mice | NIH | National Institute of Neurological Disorders and Stroke | 2023 | $544,500 | September 15, 2023 | August 31, 2025 | BAXTER, VICTORIA K | reporter.nih.gov |
| Genetic analysis of cercarial release in schistosomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $503,600 | July 3, 2017 | June 30, 2023 | ANDERSON, TIM J | reporter.nih.gov |
| Mapping the Marmoset: Characterizing the impacts of chimerism on marmoset development and aging | NIH | National Institute on Aging | 2021 | $371,926 | September 1, 2021 | August 31, 2024 | ROSS, CORINNA NICOLE | reporter.nih.gov |
| Engineering pathogen triggered biomineralization to enable a new generation of point-of-care tests | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $247,500 | April 1, 2020 | March 31, 2025 | HAYHURST, ANDREW | reporter.nih.gov |
| Determining the Functional Significance of Mutations Observed in Envelope Protein Following Serial In Vivo Passaging of Human-Simian Immunodeficiency Virus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $198,000 | August 1, 2023 | July 31, 2025 | THIPPESHAPPA, RAJESH | reporter.nih.gov |
| Determining the efficacy of a novel TB diagnostic test to monitor treatment success in drug resistant TB patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $194,892 | February 25, 2020 | January 31, 2024 | TORRELLES, JORDI B | reporter.nih.gov |
| Linking Receptor-Mediated Phagocytosis and cAMP Pathways in Macrophage Responses to Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $155,361 | April 1, 2020 | March 31, 2023 | WAGER, CHRISSY LEOPOLD | reporter.nih.gov |
| Pathogenesis of and host response to chikungunya virus infection of the central nervous system | NIH | Office of the Director, National Institutes of Health | 2022 | $118,541 | February 15, 2023 | July 31, 2024 | BAXTER, VICTORIA K | reporter.nih.gov |
| Dual Beckman Coulter DxH 690T and Beckman Coulter DxH 560 AL | NIH | Office of the Director, National Institutes of Health | 2022 | $85,775 | September 20, 2022 | September 19, 2023 | TURNER, JOANNE | reporter.nih.gov |
| Elucidate the adverse impact of mitochondria-induced oxidative stress in molecular and cellular determinants in the aging lung, driving susceptibility to Mycobacterium tuberculosis infection | NIH | National Institute on Aging | 2022 | $37,532 | September 30, 2022 | September 29, 2023 | OLMO-FONTANEZ, ANGELICA MILAGROS | reporter.nih.gov |
| EVALUATION AND TESTING SERVICES (ETS) FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $10,000 | September 30, 2025 | September 29, 2035 | CARRION, RICARDO | reporter.nih.gov |
| Pre-Clinical Models of Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $7,500 | July 15, 2024 | July 14, 2031 | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 23 | $27,153,425 | 0 | $0 |
| 2024 | 25 | $27,262,088 | 0 | $0 |
| 2023 | 25 | $34,880,811 | 0 | $0 |
| 2022 | 29 | $28,693,977 | 0 | $0 |
| 2021 | 20 | $22,451,564 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 35 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 35 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Required) | PA-24-187 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 35 awards here |
Topics of its NIH awards
- Infectious Diseases
- Emerging Infectious Diseases
- HIV/AIDS
- Rare Diseases
- Biotechnology
- Tuberculosis
- Genetics
- Biodefense and Related Countermeasures
- Lung
- Prevention
- Clinical Research
- Immunization
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.